Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Prostatic Neoplasms 12Neoplasms 11Neuroendocrine Tumors 9Breast Neoplasms 9Lung Neoplasms 6Neoplasm Metastasis 4Multiple Myeloma 4Disease 4Uterine Cervical Neoplasms 3Lymphoma, Non-Hodgkin 3Lymphoma 3Head and Neck Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Neoplastic Cells, Circulating 2Mouth Neoplasms 2Lymphoma, Follicular 2Liver Neoplasms 2Leukemia 2Hypoxia 2Hodgkin Disease 2Glioma 2Esophageal Neoplasms 2Carcinoma, Neuroendocrine 2Brain Neoplasms 2

Interventions

zirconium-89-trastuzumab 1Positron Emission Tomography Computed Tomography 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Breast Cancer Metastases × Positron Emission Tomography Computed Tomography × Clear all
NCT02286843 2021-06-18

Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?

Memorial Sloan Kettering Cancer Center

Phase NA Completed
49 enrolled 8 charts
Breast

Breast Cancer Metastases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡